Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06951867 · ClinicalTrials.gov registry record
Tezspire Cardiac Events PASS
A clinical trial of Cardiovascular Events and MACE, sponsored by AstraZeneca.
- Recruiting
- Registry status
- 16,640
- Enrollment target
- 4
- Study locations
NCT06951867 is a study of Cardiovascular Events and MACE that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 16,640 participants. The trial reports 4 study locations across 2 states.
The verdict
NCT06951867, a study of Cardiovascular Events and MACE, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- 16,640 participants
- Enrollment target
- 4
- Study locations
Study Summary
The aim of this study is to evaluate the risk of serious adverse cardiovascular events in adolescent and adult patients with severe asthma taking tezepelumab compared to a population receiving standard of care treatment for severe asthma.
Conditions Studied
Interventions
- DRUG Tezepelumab
Study Locations (4)
Other
- Danish registries (access/analysis) - Copenhagen
- French National Health Data System (SNDS) - Paris
- Team Gesundheit GKV Claims data (SHI) - Berlin
Delaware
- Healthcare Integrated Research Database (HIRD) - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16,640 participants |
| Start Date | 2025-09-15 |
| Est. Completion | 2029-05-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06951867
The ClinicalTrials.gov registry entry for NCT06951867 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 16,640 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cardiovascular Events appearing as the primary indexed condition, and to 1 intervention - of which Tezepelumab is the first listed.
NCT06951867 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Other, Delaware.
Frequently Asked Questions
What is clinical trial NCT06951867 about?
NCT06951867 is a clinical study titled "Tezspire Cardiac Events PASS". The aim of this study is to evaluate the risk of serious adverse cardiovascular events in adolescent and adult patients with severe asthma taking tezepelumab compared to a population receiving standard of care treatment for severe asthma.
What is the current status of trial NCT06951867?
This trial is currently recruiting. The enrollment target is 16,640 participants. The study started on 2025-09-15. Estimated completion is 2029-05-31.
What conditions does trial NCT06951867 study?
This clinical trial studies the following conditions: Cardiovascular Events, MACE.
What interventions are being tested in trial NCT06951867?
The interventions under investigation include: Tezepelumab (DRUG).
Who is sponsoring clinical trial NCT06951867?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06951867 being conducted?
This trial has 4 study locations across Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Events
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.